PMID- 34677249
OWN - NLM
STAT- MEDLINE
DCOM- 20211027
LR  - 20211027
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 28
IP  - 5
DP  - 2021 Oct 1
TI  - Prognostic Factors Influencing Survival and a Treatment Pattern Analysis of 
      Conventional Palliative Radiotherapy for Patients with Bone Metastases.
PG  - 3876-3890
LID - 10.3390/curroncol28050331 [doi]
AB  - BACKGROUND: Treatment indication for bone metastases is influenced by patient 
      prognosis. Single-fraction radiotherapy (SFRT) was proven equally effective as 
      multiple fractionation regimens (MFRT) but continues to be underused. OBJECTIVE: 
      Primary objectives: (a) to identify prognostic factors for overall survival and 
      (b) to analyze treatment patterns of palliative radiotherapy (proportion of SFRT 
      indication and predictive factors of radiotherapy regimen) for bone metastases. 
      METHODS: 582 patients with bone metastases who underwent conventional 
      radiotherapy between January 1st 2014-31 December 2017 were analyzed. The Cox 
      proportional hazard model was used to identify predictors of overall survival. 
      For the treatment pattern analysis, 677 radiotherapy courses were evaluated. The 
      logistic regression model was used to identify potential predictors of 
      radiotherapy regimen. RESULTS: The 3-year overall survival was 15%. Prognostic 
      factors associated with poor overall survival were multiple bone metastases 
      [hazard ratio (HR = 5.4)], poor performance status (HR = 1.5) and brain 
      metastases (HR = 1.37). SFRT prescription increased from 41% in 2017 to 51% in 
      2017. Predictors of SFRT prescription were a poor performance status [odds ratio 
      (OR = 0.55)], lung (OR = 0.49) and urologic primaries (OR = 0.33) and the 
      half-body lower site of irradiation (OR = 0.59). Spinal metastases were more 
      likely to receive MFRT (OR = 2.09). CONCLUSIONS: Based on the prognostic factors 
      we identified, a selection protocol for patients candidates for palliative 
      radiotherapy to bone metastases could be established, in order to further 
      increase SFRT prescription in our institution.
FAU - Ignat, Patricia
AU  - Ignat P
AD  - Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 
      Cluj-Napoca, Romania.
AD  - Prof. Dr. I. Chiricuta Oncology Institute, 400015 Cluj-Napoca, Romania.
FAU - Todor, Nicolae
AU  - Todor N
AD  - Prof. Dr. I. Chiricuta Oncology Institute, 400015 Cluj-Napoca, Romania.
FAU - Ignat, Radu-Mihai
AU  - Ignat RM
AUID- ORCID: 0000-0001-8162-121X
AD  - Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 
      Cluj-Napoca, Romania.
FAU - Suteu, Ofelia
AU  - Suteu O
AD  - Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 
      Cluj-Napoca, Romania.
AD  - Prof. Dr. I. Chiricuta Oncology Institute, 400015 Cluj-Napoca, Romania.
LA  - eng
PT  - Journal Article
DEP - 20211001
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
SB  - IM
MH  - *Bone Neoplasms/radiotherapy
MH  - Dose Fractionation, Radiation
MH  - Humans
MH  - Palliative Care
MH  - Prognosis
MH  - *Radiation Oncology
PMC - PMC8534390
OTO - NOTNLM
OT  - bone metastases
OT  - conventional palliative radiotherapy
OT  - multiple fraction radiotherapy
OT  - overall survival
OT  - prognostic factors
OT  - single fraction radiotherapy
COIS- The authors declare no conflict of interest.
EDAT- 2021/10/23 06:00
MHDA- 2021/10/28 06:00
PMCR- 2021/10/01
CRDT- 2021/10/22 12:17
PHST- 2021/07/31 00:00 [received]
PHST- 2021/08/24 00:00 [revised]
PHST- 2021/09/26 00:00 [accepted]
PHST- 2021/10/22 12:17 [entrez]
PHST- 2021/10/23 06:00 [pubmed]
PHST- 2021/10/28 06:00 [medline]
PHST- 2021/10/01 00:00 [pmc-release]
AID - curroncol28050331 [pii]
AID - curroncol-28-00331 [pii]
AID - 10.3390/curroncol28050331 [doi]
PST - epublish
SO  - Curr Oncol. 2021 Oct 1;28(5):3876-3890. doi: 10.3390/curroncol28050331.